The share price of Gilead Sciences, Inc. [NASDAQ: GILD] inclined by $66.36, presently trading at $66.58. The company’s shares saw 10.38% gains compared to the lowest price in the period of the last 52 weeks, set at $60.32 recorded on 09/12/19. The last few days have been benevolent to the share price as GILD jumped by +2.90% during the last week, even though the stock is still down by -2.14% compared to 1.88 of all time high it touched on 09/11/19. However, the stock had a poor performance during the past 3 months, roughly gaining 3.20%, while additionally dropping -8.13% during the last 12 months. Gilead Sciences, Inc. is said to have a 12-month price target set at $80.49. That means that the stock has a strong potential to acquire 13.91% increase from the current trading price.

Gilead Sciences, Inc. [NASDAQ:GILD]: Analyst Rating and Earnings

Its stock price has been found in the range of 60.32 to 79.61. This is compared to its latest closing price of $66.36.

Keep on the lookout for this organization’s next scheduled financial results, which are expected to be made public on Thu 24 Oct (In 41 Days).

Fundamental Analysis of Gilead Sciences, Inc. [GILD]

Now let’s turn to look at profitability: with a current Operating Margin for Gilead Sciences, Inc. [GILD] sitting at +41.00 and its Gross Margin at +78.15, this company’s Net Margin is now 26.60%. These measurements indicate that Gilead Sciences, Inc. [GILD] is generating considerably more profit, after expenses are accounted for, compared to its market peers.

This company’s Return on Total Capital is 17.70, and its Return on Invested Capital has reached 12.00%. Its Return on Equity is 26.08, and its Return on Assets is 8.14. These metrics all suggest that Gilead Sciences, Inc. is doing well at using the money it earns to generate returns.

Turning to investigate this organization’s capital structure, Gilead Sciences, Inc. [GILD] has generated a Total Debt to Total Equity ratio of 127.75. Similarly, its Total Debt to Total Capital is 56.09, while its Total Debt to Total Assets stands at 42.91. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 8.46, and its Long-Term Debt to Total Capital is 114.90.

What about valuation? This company’s Enterprise Value to EBITDA is 7.36 and its Total Debt to EBITDA Value is 2.59. The Enterprise Value to Sales for this firm is now 3.48, and its Total Debt to Enterprise Value stands at 0.35. Gilead Sciences, Inc. [GILD] has a Price to Book Ratio of 3.75, a Price to Cash Flow Ratio of 9.74 and P/E Ratio of 14.42. These metrics all suggest that Gilead Sciences, Inc. is more likely to generate a positive ROI.

Shifting the focus to workforce efficiency, Gilead Sciences, Inc. [GILD] earns $2,019,455 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 6.19 and its Total Asset Turnover is 0.33. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.30 and its Current Ratio is 3.38. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Gilead Sciences, Inc. [GILD] has 1.27B shares outstanding, amounting to a total market cap of $84.28B. Its stock price has been found in the range of 60.32 to 79.61. At its current price, it has moved down by -16.37% from its 52-week high, and it has moved up 10.38% from its 52-week low.

This stock’s Beta value is currently 1.11, which indicates that it is 2.10% more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 57.84. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Gilead Sciences, Inc. [GILD] a Reliable Buy?

Shares of Gilead Sciences, Inc. [GILD], overall, appear to be a solid investment option, with Wall Street analysts expecting its price to rise considerably in the next 12 months. This company generates high value from the labor resources and other capital it has available, and while it has heavy Long-Term Debt to Equity, the majority of the metrics point to this investment being highly attractive.